Johnson & Johnson
$670.11B- Market cap
- $641.88B
- Debt
- +$47.94B
- Cash
- −$19.71B
Capital structure 93% equity / 7% debt · EV / Revenue 7.11x
Quick read
Fair value engine
Each company valued on the other's multiple, then compared with the market price.
JNJ · price snapshotP/E 24.15x
$266.35Snapshot Sep 10, 2026, 4:00 PM ET
Implied fair value · at MRK's multiple
$219.2517.7% below market
11.03 JNJ Annual EPS×19.88x MRK P/E=$219.25
Market $266.35Implied $219.25
MRK · price snapshotP/E 19.88x
$144.71Snapshot Sep 10, 2026, 4:00 PM ET
Implied fair value · at JNJ's multiple
$175.8021.5% above market
7.28 MRK Annual EPS×24.15x JNJ P/E=$175.80
Market $144.71Implied $175.80
Metric by metric
Smart diff
Where each company leads, and how wide the gap is.
6 metrics shown
MetricJNJMRKDifference (JNJ − MRK)
Revenue growth (YoY)
Growth edge
6.0%
1.3%
JNJ: higher Revenue growth (YoY) by 4.7 percentage points
Gross margin
Reported gross margin
67.9%
74.8%
MRK: higher Gross margin by 6.9 percentage points
EBITDA proxy margin
Operating income + D&A
N/M
N/M
Insufficient data
EV/Revenue
Multiple premium
7.11x
6.03x
MRK: lower EV/Revenue by 1.1x
P/E
Higher P/E
24.15x
19.88x
MRK: lower P/E by 4.3x
Net debt / EBITDA proxy
Lower leverage
N/M
N/M
Insufficient data
Statements
Side-by-side financials
Annual statements in reported currencies, with calculations and source evidence.
Income statement · reported unitsJNJMRKDelta
RevenueEnded 2025-12-28Ended 2025-12-31+USD 29.18B
Gross profitEnded 2025-12-28Ended 2025-12-31+USD 15.31B
Operating income—
EBITDA proxy—
Net incomeEnded 2025-12-28Ended 2025-12-31+USD 8.55B
Diluted / combined EPS (reported share)Ended 2025-12-28Ended 2025-12-31Different share bases
Revenue growthEnded 2025-12-28Ended 2025-12-31+4.7 pp
Gross marginEnded 2025-12-28Ended 2025-12-31−6.9 pp
Operating margin—
EBITDA proxy margin—
Net marginEnded 2025-12-28Ended 2025-12-31+0.4 pp
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Historical trends
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
JNJMRK
Price framework
Enterprise value
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Merck & Co., Inc.
Price framework
Intrinsic value (DCF)
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
$115.89−56.5% vs $266.35
$281.54B equity value÷2.43B shares=$115.89
Bear
$93.96
Base
$115.89
Bull
$146.14
Cash-flow base$20B
Growth2.3%
Balance sheet health
Solvency
Inspect reported liquidity and leverage alongside historical financial-health checks.
Piotroski F-Score
Financial strength on a 0–9 scale.
3/ 9 · JNJWeak
4/ 9 · MRKModerate
Altman Z-Score
Bankruptcy-risk signal from balance sheet and earnings power.
5.30
Comparable set
Relative positioning
Where the pair sits against the wider comparable set.
Keep comparing
More comparisons
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.